← All trials
NCT03341754
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2018
- Primary completion
- Dec 30, 2019
- Completion date
- Oct 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 52
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- United States ArmyLead sponsor
- United States Agency for International DevelopmentCollaborator
- United States ArmyCollaborator
- United States NavyCollaborator
- University of OxfordCollaborator
- United States ArmyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.